Latest News and Press Releases
Want to stay updated on the latest news?
-
PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) Phase II Part I trial of...
-
PDC-1421 high-dose data meets primary endpoint on MADRS scale in ITT clinical trial population PDC-1421 low-dose and PDC-1421 high-dose each proved safe, were well-tolerated, and had no...
-
· Dr. Andrew Chang, principal investigator, recently presented encouraging feasibility study results from Vitargus® at the AAO 2019 Annual Meeting · Study results suggest Vitargus®...
-
· Dr. Andrew Chang, principal investigator, will present encouraging results on Vitargus® from recently completed feasibility study · Company to initiate multi-national,...
-
FREMONT, CA, Oct. 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical stage biopharmaceutical company developing...
-
Fremont, CA, Sept. 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical stage biopharmaceutical company developing...
-
Collaboration combines BioLite Japan’s early-stage discovery capabilities with the Company’s clinical trial expertise BioLite Japan’s expertise in academic and medical community in Japan and...
-
FREMONT, CA, Aug. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical stage biopharmaceutical company developing...
-
FREMONT, CA, June 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical stage biopharmaceutical company developing...